ovarian cancer

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

News

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

Oncology

pharmaphorum podcast Episode 185a - Dr Stacy Lindborg

IMUNON at ASCO 2025: Changing the micro-tumour environment i...

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

Sutro puts lead ADC on hold, cuts staff and changes CEO

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.

Oncology

Harnessing IL-12: Immunotherapy research advances may enhanc...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer recurrence, more effective disease maintenance strategies, more preci

AbbVie joins BMS in taking a hard line on UK drug pricing

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

IMUNON at ASCO 2025: Changing the micro-tumour environment i...

AbbVie builds the case for ovarian cancer drug Elahere

Sutro puts lead ADC on hold, cuts staff and changes CEO

Harnessing IL-12: Immunotherapy research advances may enhanc...

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

ovarian cancer

Editor's Picks